Mucormycosis: A Short Dental Review
Abstract
Mucormycosis is a severe and often fatal fungal infection that primarily affects immunocompromised patients. This serious infection is caused by a group of molds found in our environment called mucormycetes. Those with reduced ability to fight infections are most at risk including those with uncontrolled diabetes and malignancies. Historically, this fungal infection was rare, however, in recent years the prevalence has increased and the need for further discussion is warranted. The prevalence of Mucormycosis is significantly higher in India compared to other countries. In the wake of COVID-19, an increased number of cases have been reported in India, bringing additional attention to this deadly disease. Mucormycosis is categorized by the area of infection and includes five major clinical forms; pulmonary, disseminated, rhinocerebral, cutaneous, and gastrointestinal. Due to a high mortality rate, aggressive treatment is recommended to improve patient outcomes. Early diagnosis along with combination treatment is vital for patient survival. This paper intends to provide a brief overview and discussion of recent advances. The main aim and purpose of this review is to increase awareness and understanding of this disease to improve early diagnosis and outcomes.
References
Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:2-9. doi: https://doi.org/10.1111/j.1469-0691.2009.02972.x
Mucormycosis NORD (National Organization for Rare Disorders). Danbury (CT): 2018, Sep 21 [Cited May 25, 2023.] available at: https://web.archive.org/web/20210526161509/https:/rarediseases.org/rare-diseases/mucormycosis/
Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998 Nov;27(5):1138-47. https://pubmed.ncbi.nlm.nih.gov/9827260/
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An Update. Journal of Fungi (Basel). 2020 Nov 2;6(4):265. doi: https://doi.org/10.3390/jof6040265
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34. doi: https://doi.org/10.1093/cid/cir866
Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol. 2013;8(9):1163-1175. doi: https://doi.org/10.2217/fmb.13.78
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569. doi: https://doi.org/10.1128/CMR.18.3.556-569.2005
Agha FP, Lee HH, Boland CR, Bradley SF. Mucormycoma of the colon: early diagnosis and successful management. AJR Am J Roentgenol. 1985;145(4):739-741. doi: https://doi.org/10.2214/ajr.145.4.739
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: https://doi.org/10.1086/432579
Spellberg B, Edwards Jr. J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005 Jul;18(3):556-69. doi: https://doi.org/10.1128/CMR.18.3.556-569.2005
Prakash H., Ghosh A.K., Rudramurthy S.M., Singh P., Xess I., Savio J., Pamidimukkala U., Jillwin J., Varma S., Das A., et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med. Mycol. 2018 Jun 1;57(4):395-402. doi: https://doi.org/10.1093/mmy/myy060
Fürbringer P. Beobachtungen über Lungenmycose beim Menschen. Virchows Arch. 1876;66:330–365.
Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012 Feb;54 Suppl 1:S55-60. doi: https://doi.org/10.1093/cid/cir868
Chakrabarti A., Das A., Mandal J., Shivaprakash M.R., George V.K., Tarai B., Rao P., Panda N., Verma S.C., Sakhuja V. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol. 2006;44:335–342. doi: https://doi.org/10.1080/13693780500464930
Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms. 2021;9( 3):523. doi: https://doi.org/10.3390/microorganisms9030523
Chakrabarti A., Das A., Sharma A., Panda N., Das S., Gupta K., Sakhuja V. Ten Years’ Experience in Zygomycosis at a Tertiary Care Centre in India. J. Infect. 2001;42:261–266. doi: https://doi.org/10.1053/jinf.2001.0831
Chakrabarti A., Das A., Mandal J., Shivaprakash M.R., George V.K., Tarai B., Rao P., Panda N., Verma S.C., Sakhuja V. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol. 2006;44:335–342. doi: https://doi.org/10.1080/13693780500464930
Chakrabarti A., Chatterjee S.S., Das A., Panda N., Shivaprakash M.R., Kaur A., Varma S.C., Singhi S., Bhansali A., Sakhuja V. Invasive zygomycosis in India: Experience in a tertiary care hospital. Postgrad. Med. J. 2009;85:573–581. doi: https://doi.org/10.1136/pgmj.2008.076463
Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India. Emerging Infectious Diseases. 2021;27(9):2349-2359. doi: https://doi.org/10.3201/eid2709.210934
International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org
Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis. 2007 Apr 15;44(8):1089-90. doi: https://doi.org/10.1086/512817
Bitar D, Lortholary O, Le Strat Y et al. Population-based analysis of invasive fungal infections. Emerg Infect Dis. 2014; 20: 1149–1155. doi: https://doi.org/10.3201/eid2007.140087
Gamaletsou MN, Drogari-Apiranthitou M, Denning DW, Sipsas NV. An estimate of the burden of serious fungal diseases in Greece. Eur J Clin Microbiol Infect Dis. 2016;35(7):1115-1120. doi: https://doi.org/10.1007/s10096-016-2642-8
Sen M, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021 Jul;69(7):1670-1692. doi: https://doi.org/10.4103/ijo.IJO_1565_21
Dannaoui E, Lackner M. Special Issue: Mucorales and Mucormycosis. J Fungi (Basel). 2019 Dec 23;6(1):6. doi: https://doi.org/10.3390/jof6010006
Walsh T.J., Hospenthal D.R., Petraitis V., Kontoyiannis D.P. Necrotizing mucormycosis of wounds following combat injuries, natural disasters, burns, and other trauma. J. Fungi. 2019;5:(3)57. doi: https://doi.org/10.3390/jof5030057
Gupta MK, Kumar N, Dhameja N, Sharma A, Tilak R. Laboratory diagnosis of mucormycosis: Present perspective. J Family Med Prim Care. 2022 May;11(5):1664-1671. doi: https://doi.org/10.4103/jfmpc.jfmpc_1479_21
Lass-Flörl C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:60-5. doi: https://doi.org/10.1111/j.1469-0691.2009.02999.x
Gupta N, Srinivas S, Harikumar A, Devaraja K, Nallapati VT, Saravu K. Deoxycholate amphotericin for management of mucormycosis: a retrospective cohort study from South India. Infez Med. 2022 Sep 1;30(3):432-439. doi: https://doi.org/10.53854/liim-3003-12
Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis. 2003;37(3):415-425. doi: https://doi.org/10.1086/376634
Spellberg B, Witt MD, Beck CK. Amphotericin B: is a lipid-formulation gold standard feasible?. Clin Infect Dis. 2004;38(2):304-307. doi: https://doi.org/10.1086/380844
Nithyanandam, S., M. S. Jacob, R. R. Battu, R. K. Thomas, M. A. Correa, and O. D'Souza. 2003. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J. Ophthalmol. 51:231-236. https://pubmed.ncbi.nlm.nih.gov/14601848/
Khor, B. S., M. H. Lee, H. S. Leu, and J. W. Liu. 2003. Rhinocerebral mucormycosis in Taiwan. J. Microbiol. Immunol. Infect. 36:266-269. https://pubmed.ncbi.nlm.nih.gov/14723256/
Symeonidis AS. The role of iron and iron chelators in zygomycosis. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:26-32. doi: https://doi.org/10.1111/j.1469-0691.2009.02976.x
Couch, L., F. Theilen, and J. T. Mader. 1988. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch. Otolaryngol. Head Neck Surg. 114:791-794. doi: https://doi.org/10.1001/archotol.1988.01860190095032
Robb, S. M. 1966. Reactions of fungi to exposure to 10 atmospheres pressure of oxygen. J. Gen. Microbiol. 45:17-29. doi: https://doi.org/10.1101%2Fcshperspect.a019562
